Use of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs and Cancer Risk.

ABSTRACT:

Importance

The Oral Rheumatoid Arthritis Trial Surveillance demonstrated an increased cancer risk among patients with rheumatoid arthritis (RA) taking tofacitinib compared with those taking tumor necrosis factor inhibitors (TNFis). Although international cohort studies have compared cancer outcomes between TNFis, non-TNFi drugs, and Janus kinase inhibitor (JAKis), their generalizability to US patients with RA is limited.

Objective

To assess the comparative safety of TNFis, non-TNFi drugs, and JAKis among US patients with RA (ie, the cancer risk associated with the use of these drugs among these patients).

Design, setting, and participants

This retrospective cohort study used US administrative claims data from Merative Marketscan Research Databases from November 1, 201

SUBMITTER: Sendaydiego X 

PROVIDER: S-EPMC11579790 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature